Heterobicyclo-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A
View Patent ↗Disclosed are compounds of Formula G1 (structurally represented): where “RG3” “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.
1. A compound, or a pharmaceutically acceptable salt thereof, which is:
wherein:
each R Gda is, independently: (a) H; (b) methyl; or (c) ethyl; and
R Ge is:
2. A compound of claim 1 which is:
2-(2-(2-cyclopropyl-4H-pyrrolo[3,4-d]thiazol-5(6H)-yl)ethyl)-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine;
2-(2-(2-isopropyl-4H-pyrrolo[3,4-d]thiazol-5(6H)-yl)ethyl)-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine;
2-(2-(2-ethyl-4H-pyrrolo[3,4-d]thiazol-5( 6 H)-yl)ethyl)-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]oxazol-5(6H)-yl)ethyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine;
2-(2-(2-cyclopropyl-4H-pyrrolo[3,4-d]oxazol-5(6H)-yl)ethyl)-7-methoxy -[1,2,4]triazolo[1,5-c]quinazolin-5-amine;
7-methoxy-2-(2-(1-methylpyrrolo[3,4-c]pyrazol-5(1H,4H,6H)-yl)ethyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]oxazol-5(6H)-yl)propyl) -[1,2,4]triazolo[1,5-c]quinazolin-5-amine;
(R)-7-methoxy-2-(2-(2-methyl-4H-pyrrolo[3,4-d]oxazol-5(6H)-yl)butyl) -[1,2,4]triazolo[1,5-c]quinazolin-5-amine,
or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition that comprises an inert carrier and the compound of claim 1 , or pharmaceutically acceptable salt thereof.
4. A compound of the Formula:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4 which is:
6. The compound of claim 4 in the form of a pharmaceutically acceptable salt.
7. A pharmaceutical composition comprising an inert carrier and the compound of claim 4 or a pharmaceutically acceptable salt thereof.
8. A compound of the Formula:
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 8 , which is:
10. The compound of claim 8 in the form of a pharmaceutically acceptable salt.
11. A pharmaceutical composition comprising an inert carrier and the compound of claim 8 or a pharmaceutically acceptable salt thereof.
12. A compound of the Formula:
or a pharmaceutically acceptable salt thereof.
13. The compound of claim 12 which is:
14. The compound of claim 12 in the form of a pharmaceutically acceptable salt.
15. A pharmaceutical composition comprising an inert carrier and the compound of claim 12 or a pharmaceutically acceptable salt thereof.